Anti-TNF Withdrawal in Inflammatory Bowel Disease
The introduction of the anti-tumor necrosis factorα agents (anti-TNFα) in clinical practice has greatly advanced the treatment of inflammatory bowel disease. The use of these medications results in durable remission in a subset of patients, preventing surgery and hospitalizations. However, there are some concerns about safety and costs associated with their long-term use. Therefore, anti-TNF withdrawal has emerged as an important consideration in clinical practice. Herein our goal was to discuss the available evidence about anti-TNFα discontinuation in IBD that could inform the clinician on the expected rates of relapse, the potential predictors of relapse, as well the response to re-treatment.
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Digital revista |
| Language: | English |
| Published: |
Sociedade Portuguesa de Gastrenterologia
2016
|
| Online Access: | http://scielo.pt/scielo.php?script=sci_arttext&pid=S2341-45452016000300006 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|